1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Acute coronary syndromes

Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions

Medtech innovation briefing [MIB89] Published: 29 November 2016

  • Overview
  • Summary
  • The technology
  • Regulatory information
  • Equality considerations
  • Clinical and technical evidence
  • Specialist commentator comments
  • Specialist commentators
  • Development of this briefing
Download (PDF)

Advice

  • Next

NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions.

What are MIBs?


  • Next